GLP's
Retatrutide + Cagrilintide
20 mg + 5 mg
Triple agonist research peptide (GIP / GLP-1 / glucagon)
$140
Composition
Retatrutide 20 mg, Cagrilintide 5 mg
Research overview
Retatrutide is an investigational multi-receptor agonist studied in metabolic research for interactions with GIP, GLP-1, and glucagon pathways. Published human studies and newer late-stage trial updates focus on body weight, glycemic markers, cardiometabolic endpoints, and tolerability.
Potential research areas
- GIP / GLP-1 / glucagon signaling
- Metabolic research models
- Appetite and energy-balance pathways
- Body-composition endpoints
- Form
- Lyophilized Powder
- Category
- Research Peptide
- Use
- Research Only
Current evidence varies by compound. Many products discussed in this guide remain investigational, are not approved for general clinical use, and should only be handled under qualified research protocols.
No dosing, administration, or treatment instructions are provided.